AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 81 min read$BLLN

Atay Oguzhan sold $1.5M of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 12,500 indirectly-held shares of BillionToOne, Inc. (BLLN) at an average of $122.05 ($118.81–$124.74, $1.53M total) across 14 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Jul 8, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

Traders may briefly reassess sentiment due to insider selling, but the pre-arranged nature reduces interpretive weight versus an unplanned sale.

02

Market read

A $1.53M open-market insider sale under 10b5-1 is disclosed, likely causing only marginal sentiment impact absent other catalysts.

03

What to watch

The article notes indirect holdings and multiple small trades; without context on total insider ownership changes over time, the signal is limited.

Relevance 5/10Novelty 4/10Timing: today’s SEC Form 4 disclosure, after-hours filing timestamp

Background

The filing is an SEC Form 4 insider transaction by the company’s Chairman and CEO, explicitly tied to a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CEO Atay Oguzhan sold $1.53M of BLLN shares via a Rule 10b5-1 plan, filing a Form 4 on July 8.

Expected impact

Likely minimal, though it can add short-term overhang if traders interpret it as supply or confidence signal.

Evidence & confidence

The filing specifies an open-market sale and confirms a pre-arranged 10b5-1 plan; the article provides no new operational, financial, or regulatory catalyst.

Market effects

Sector

No sector-level read-across; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales are often mechanical and may reflect diversification or liquidity needs rather than bearish expectations.

Key entities

  • issuer
    BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Atay Oguzhan

    Chairman and CEO who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLLN insider trading history →

Related articles

OCT 7
$BLLNLow

BillionToOne's Northstar Response Shows High Concordance In Advanced Cancer Study

BillionToOne (BLLN) published a study showing its Northstar Response liquid biopsy assay had high concordance with a commercial ctDNA assay in advanced cancer patients. The study of 61 patients found 94% agreement in tumor burden change direction, with Northstar Response aligning with clinical ground truth in discordant cases. The assay detects disease progression even when tumors evolve post-biopsy. BLLN shares closed at $22.71, down 0.79%.

rttnews.com2 min
OCT 7
$BLLNMedAI 8/10

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.

globenewswire.com2 min
AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
AUG 5
$BLLNMed

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

SEC EDGAR 8-K7 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min